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Purpose/Aim of the study: To assess if corneal epithelium can be cultured ex-vivo from corneas 
eviscerated due to irretrievable trauma, according to a cell culture method which made use of 
autologous platelet-rich plasma (A-PRP) as culture substrate. To compare corneal epithelium 
cultured ex vivo from corneas eviscerated following trauma using A-PRP combined  with DMEM 
(Dulbecco’s modified Eagles medium), versus DMEM alone.  
Materials and Methods: This was a laboratory case controlled study of human corneal cells 
cultured in a mixture of A-PRP and DMEM, versus DMEM alone from 6 eviscerated corneas. A 
hundred explants were created of which fifty explants were plated on A-PRP-gel construct 
combined with DMEM and fifty controls were placed in serum free DMEM alone. Donor 
patients received systemic antibiotics prior to evisceration. 
Results: Confluent epithelium in mono-layers could be cultured when donor limbal biopsies 
were placed in a mixture of A-PRP culture medium and DMEM. No growth were observed when 
corneas were placed in serum-free DMEM medium only (p<0.05). No bacterial infection was 
observed in cultures. 
Conclusions: This study demonstrated that autologous platelet rich plasma is a viable and 
effective alternative to bovine serum for the ex-vivo expansion of limbal epithelial cells. It also 
shows that eviscerated corneas are a viable source of donor tissue for this purpose in South 
Africa where access to tissue banks is limited. 
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Figure 1. Epithelium (blue arrow) is seen expanding from the “hill” or forming 
face (red arrow). 3D Proliferation is demonstrated here where the “hill” is out of 
focus due to proliferation in the vertical axis, whereas the “valley” is in focus, 
representing epithelium in a horizontal layer. 
 
Figure 2. The corneal explant (blue arrow) is surrounded by a lucid area of 
epithelium (red arrow) in PRP. 
 
Figure 3. Epithelium (red arrow) is seen proliferating in a monolayer from the 
limbus (blue arrow). 
 
Figure 4. Hematoxylin and eosin (H&E) stain demonstrating squamous epithelial 
cells at the proliferating edge (green arrow). Notice the dense configuration of 






Abbreviations appear chronologically as they are encountered in the text. Abbreviations are 
explained within the text as well. 
LESCs:   limbal epithelial stem cells 
LSCD:   limbal stem cell deficiency 
KLAL:   keratolimbal lamellar allograft 
CLAU:   conjunctival-limbal autografts 
lr-CLAL:  living-related conjunctival-limbal allografts 
PRP:   platelet rich plasma 
A-PRP:  autologous platelet-rich plasma 
SLET:   simple limbal epithelial transplantation 
DMEM:  Dulbecco’s modified Eagles medium 
LECs:   limbal epithelial cells 
H & E:   Haematoxylin and Eosin 
COASTL:  The Clinical Outcome Assessment in Surgical Trials of Limbal Stem cell 
deficiency tool 
HIV:   human immunodeficiency virus 
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MIV:                 menslike immuungebrek virus  
SJS:   Stevens–Johnson Syndrome 
ARV:   anti-retroviral medication 
THT:   tapered head tube 
CO2:   carbon dioxide 
HEPA:   high-efficiency particulate air 
TGF-β:  transforming growth factor beta 
b-FGF:   basic fibroblast growth factor 
IGF-1:   insulin-like growth factor 1 
PDGF:   platelet-derived growth factor 
VEGF:   vascular endothelial growth factor 








CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
Eviscerated Corneas as Tissue Source for Ex Vivo Expansion of Limbal Epithelial Cells on 
Platelet-Rich Plasma Gels 
Introduction 
 
Conditions such as Stevens–Johnson syndrome, ocular pemphigoid, and chemical and thermal 
injuries may destroy the limbal stem cells of the cornea, and lead to scarring of the cornea.1  
When limbal epithelial stem cells (LESCs) are destroyed by trauma or disease, conjunctiva and 
peripheral blood vessels migrate on to the cornea.2  This may lead to vision loss and 
discomfort.2 Normal corneal epithelium needs to be restored in order for a normal refractive 
surface to be established. Corneal repair could be achieved through the ex vivo culture of 
corneal epithelium.3,4 
The use of animal products in media does not accommodate for all religious and cultural beliefs 
in the multicultural society of South Africa, and donor corneas are too scarce for culturing to be 
efficiently rolled out. In order for us to be able to give our population state of the art stem cell 
transplants to save their sight, we need to design a resource-based protocol for culturing stem 




Relevant Anatomy and Physiology 
 
Limbal stem cells possess the inherent ability to differentiate into epithelial cells, which cover 
and thus maintain the integrity of the cornea. Stem cells are situated in the limbus and in the 
limbal palisades.2 Shortt states that there is still uncertainty regarding the exact distribution of 
stem cells in the limbus.2 The corneal epithelium is constantly reproduced by the limbal stem 
cells of the cornea. Deficiency of limbal stem cells prevents the formation of new epithelial cells 
and thus epithelial defects and conjunctivalization of the cornea may develop. LESCs are 
situated within the basal cell layer of the limbal epithelium and have characteristics of a stem 
cell phenotype.2 To date no specific cell markers exist to define corneal limbal stem cells.2 
The corneal epithelium is responsible for maintaining a clear cornea and regular refractive 
surface.2 As seen in the skin, desquamated corneal epithelial cells are replenished by LESCs 
located in the limbus.2 Shortt et al. state that limbal stem cell deficiency (LSCD) is associated 
with the loss of limbal palisades suggesting that LESCs reside within the limbal palisades.2 
Currently there is uncertainty regarding the precise distribution of stem cells within the limbus.2 
Chen et al. demonstrated that the basal cells of the superior limbus have characteristics of a 
stem cell phenotype.2,5 Dua on the other hand, described limbal epithelial crypts, which is a 
niche structure where the LESCs are located.6 This study reported an average of six limbal 





Diagnosing limbal stem cell deficiency (LSCD) 
 
Shortt and colleagues mention that LSCD is characterized by the ingrowth of conjunctiva onto 
the cornea with a resultant epithelial haze, sub-epithelial vascularization, persistent or 
recurrent epithelial defects and loss of the limbal palisades of Vogt.2 LSCD may also be classified 
as total or partial.2 Partial LSCD is characterized by localized loss of LESC with the ingrowth of 
conjunctiva in these areas of stem cell loss.2 
 
Management of LSCD  
 
Conservative management of LSCD includes lubrication, bandage contact lenses, and 
autologous serum eye drops.2 Shortt mentions that only the use of autologous serum is 
supported by evidence in the literature.2,7 
Surgical means to manage LSCD include debridement of migrating conjunctival epithelium and 
the transplantation of amniotic membrane.2,8,9 Shortt et al. mention that a variety of methods 
may be used to transplant limbal stem cells, which include keratolimbal lamellar allograft 
(KLAL), oversized or eccentric penetrating keratoplasties, conjunctival-limbal autografts (CLAU) 
and living-related conjunctival-limbal allografts (lr-CLAL).2,10–14 Shortt states that the removal of 
limbus is not without risk, and that partial stem cell deficiency may develop following limbal 





Summary and interpretation of literature, and its implications for the research 
 
Historically corneal epithelium has been cultured ex-vivo with the use of lethally irradiated 3T3-
J2 feeder cells and a fibrin-substrate combined with fetal-calf serum to facilitate expansion of 
limbal corneal stem cells and holoclones.3 Rama et al. state that this culture method has been 
used worldwide since the 1980s.3 The first pivotal article on the expansion of corneal 
epithelium was published by Pellegrini et al. in 1997.16 Following the ground-breaking research 
of Graziella Pellegrini, similar methods have been used to expand corneal epithelium.4,17 Most 
of these methods all use exogenous products in culture media, such as lethally irradiated feeder 
fibroblasts and fetal-calf serum.4,16,17 In this research we are aiming to establish the growth of 
corneal epithelium without the use of any animal or exogenous products. This will potentially 
eliminate the transmission risk of blood borne diseases.  
Other researchers have succeeded in culturing corneal epithelium without the use of murine 
3T3 feeder cells.18–21 Cell sheet carriers used included denuded amniotic membrane, Matrigel, 
Myogel and stromal extract,18 as well as soft contact lenses.20,21 Di Girolamo also succeeded in 
culturing epithelium with the use of autologous serum.20,21 In our research project epithelial 
cells will be cultured on platelet rich plasma (PRP), using the REGEN PRP® system.22,23 The PRP 
will be created from the patient’s own blood and is therefore also called autologous platelet-
rich plasma or A-PRP.23 We plan to ‘activate’ the plasma with calcium since this enhances cell 
proliferation and -migration.23  
The transplant of corneal epithelium onto stem cell deficient corneas has been attempted with 
success by previous researchers, e.g. Tsubota et al. (1999), Koizumi et al. (2001) and Shimazaki 
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et al. (2002).1,4,24 Nakamura et al. demonstrated that it is possible to produce sufficiently 
stratified, well differentiated, autologous cultivated corneal limbal epithelium on amniotic 
membrane from a minimal biopsy of the donor eye and to transplant it onto the injured eye.25 
At 19 months post-transplantation the corneas were stable with no epithelial defects.25  
Koizumi also showed that cultivated corneal epithelium had four to five layers of stratification 
and was well differentiated.4 Corneas which received stem cell transplants provided evidence of 
the persistence of donor epithelial cells up to 3.5 years after limbal allograft transplantation.26 
A new method of corneal limbal epithelial transplantation is termed SLET (simple limbal 
epithelial transplantation) and involves the creation of an in vivo culture environment on the 
patient’s cornea.27,28 Our culture method, using A-PRP, can also be applied in SLET. After 
sufficient epithelium has been cultured this can then be transplanted onto amniotic membrane 
‘epithelial side up’ and sandwiched between an amniotic membrane covering it ‘epithelial side 
down’. The newly cultured epithelium should then eventually cover the whole amniotic 
membrane and cornea. Eventually only epithelium is left to cover the corneal stroma, as the 
amniotic membrane degrades.   
Substrates other than amniotic membrane may also be used as carriers. Francis et al. compared 
different substrates to grow corneal epithelial cells on.18 Substrates included denuded amniotic 
membrane, Matrigel, Myogel and stromal extract.18 The most rapid growth was observed on 
Myogel and denuded amniotic membrane and these two cell carriers also provided the most 
reliable substrata for achieving confluent epithelial growth.18 Myogel may be obtained from an 
autologous muscle biopsy.18 Nakamura et al. and Francis et al. used autologous serum as 
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substrate to culture corneal epithelium on to amniotic membrane and it is this method that we 
will follow in our protocol, but without the use of amniotic membrane or any other exogenous 
products.18,25 This makes our proposed culture method novel. 
Corneal stem cells were cultured with different mixtures of culture media. Utheim et al. used 
mixtures which contained dispase, Dulbecco’s modified Eagles medium (DMEM), sodium 
bicarbonate, Ham’s F12 solution, fetal bovine serum, dimethyl sulphoxide, human epidermal 
growth factor, insulin, transferrin, selenium, hydrocortisone, cholera toxin, gentamicin, 
amphotericin B and vancomycin.29 Pellegrini et al. used lethally irradiated 3T3-J2 cells to 
stimulate epithelial growth.16 The method that we will use differs from previous research in 
that we will not use murine irradiated feeder fibroblasts or any other exogenous or animal 
products in our cultures. We will solely rely on growth factors released from plasma to 
stimulate epithelial growth.  
A medline search was performed to review the literature for any malignancy incurred following 




Corneal stem cells are usually cultured on a denuded amniotic membrane carrier and then 
attached to epithelial defects.4 Corneal stem cells were obtained from cadaver corneas as 
allografts, as living related conjunctival limbal allografts or they were obtained as autografts 
from the same patient via corneal button biopsies on the limbal area from the contralateral 
eye.30,31 In contrast to the normal methods used for harvesting corneal limbal stem cells, we 
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aim to harvest corneas from eyes which obtained irretrievable loss of vision due to trauma. In 
our search of the literature no studies could be found which investigated the culturing of 
corneal epithelium from eviscerated corneas. What makes our study novel is the fact that 
corneal cells will be grown from eviscerated corneas obtained due to trauma and not from 
cadaver corneas or from limbal biopsies as in previous research.18,21  
 
Ex vivo cultured limbal epithelial cells 
 
The ex vivo expansion of corneal epithelium is based on the pioneering research of epithelial 
expansion of skin by Rheinwald and Green.2,32–34 Limbal cells are usually harvested from the 
contralateral healthy eye in the form of a small 2×2mm2 biopsy.2 If the patient has bilateral 
total LSCD, then Shortt et al. advises that allogeneic limbal epithelium be harvested from living 
related donors or from fresh cadaveric tissue.2 The limbal biopsy contains a population of 
LESCs, which are cultured and expanded in a laboratory to produce a sheet of LECs (limbal 
epithelial cells) that is suitable for transplantation onto the diseased cornea following removal 
of the abnormal conjunctivalized epithelium.2  
Shortt et al. state that the advantage of the ex vivo expansion of epithelium is twofold.2 Firstly 
the required limbal biopsy is smaller than biopsies used in CLAU and lr-CLAL and this reduces 
the risk of stem cell failure in the donor eye.2 The smaller sized biopsy also provides the option 
of taking a further biopsy if needed.2 Secondly, due to the absence of antigen-presenting 




Researchers have also used oral mucosal epithelium as a source of stem cells for the ex vivo 
expansion of epithelium.2 Both corneal epithelium and mucosal epithelium express keratin 3 
and mucosal epithelium is thought to be at a lower stage of epidermal differentiation than 
corneal epithelium.2 Since the mucosa from the same patient is autologous there is no risk of 
immune mediated rejection.2 For the purpose of this research we will focus on the expansion of 




 To assess if corneal epithelium can be cultured ex-vivo, in a tissue culture laboratory 
from corneas eviscerated due to irretrievable trauma according to a novel cell culture 
method, with the exclusion of animal products and without the use of 3T3-feeder 
fibroblasts.  
 To establish if A-PRP is essential for cultivating epithelium.  
 The results of this study will create a pool of standardized data on culturing corneal 











The results will be presented to a large degree with statistical analysis of cell counts evolving 
from each explant within A-PRP culture-medium. Cells will be confirmed as epithelium by 
means of Haematoxylin and Eosin (H & E) staining and Masson-Trichrome staining and by 
means of K3 staining and K12 staining.4,17,25,36,37 Inverted phase contrast microscopic digital 
photographs at magnifications of 100 times and 200 times will be taken at weekly intervals to 
monitor the growth of cultured mono-layers.37 Success will be classified as the generation of at 
least one complete mono-layer of cells ex-vivo on a substrate. Cell proliferation in the cell 
sheets will be photographically counted using a micrometer and eye-piece grid, which will be 




Corneal stem cells may also be harvested from damaged or traumatized corneas, since only a 
small portion of the limbus is required to culture new cells. Due to the very high incidence of 
irreparably damaged corneas following trauma, we currently have a vast source of limbal cells 
in South Africa.38 Corneas which have to be eviscerated due to trauma, may now also be used 
as a source of limbal stem cells to culture normal corneal epithelium from. We would like to see 
if we can successfully cultivate limbal stem cells from corneas obtained from irreparably 




The benefit of ex vivo transplantation of limbal stem cells 
 
Limbal stem cell transplantation may reduce inpatient stay in hospital wards by expediting the 
healing process of persistent epithelial defects. Inevitably this will reduce the burden on our 
over full wards and will also lead to considerable financial savings for the state sector, since 
inpatient stay will be shorter. 
Traditionally, patients with persistent epithelial defects require a much longer stay in hospital 
due to the chronicity of these defects, compared to other ophthalmological conditions. These 
defects are usually treated with lubricants, punctal occlusion, pressure patching, debridement 
of the epithelial defect and tarsorrhaphy of the eyelids.39 A temporary ptosis by means of 
injecting Botulinum toxin into the upper eyelid may also be considered. These defects may also 
be covered with a bandage soft contact lens which aids the regeneration process by protecting 
the advancing epithelium from being sloughed off.39 Amniotic membrane is useful in resistant 
cases since the growth factors released may stimulate epithelial growth and reduce 
inflammation.39 Topical autologous serum drops, created from the patient’s own blood, may 
also be used to promote epithelialization through the release of essential growth factors.39 
Scleral contact lenses may promote enhanced oxygenation and promote epithelialization.39 
Limbal stem cell transplantation or ex vivo cultivated epithelium may also be considered if 






Patients included in this study must have obtained irreparable eye trauma and may only 
partake in this study if they sign informed consent for evisceration. Clear guidelines for the 
indication of evisceration will be followed, which includes (i) no perception of light, (ii) gross 
damage to an eye due to trauma not salvageable with suturing, (iii) total afferent pupillary 




Patients who are not willing to partake and who have not signed informed consent. 
Patients not exposed to eye trauma. 
Patients still experiencing perception of light in their traumatized eye. 
 
Identification of gaps or needs for further research 
 
Shigeto Shimmura and Kazuo Tsubota mention an urgent need for more research regarding the 
transplant of corneal stem cells in the American Journal of Ophthalmology.35 They state that 
‘techniques for cultivating epithelial sheets vary greatly from one report to another, all of which 
seem to show clinically successful patients.’ 35 They also state that the overall number of 
patients reported with this surgical technique is relatively small, and that further reports are 
anticipated to determine the advantages of cultivated sheets over conventional limbal 
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transplants.35 We will be using a standardized method for cultivating corneal epithelial cells as 
developed by our laboratory team and obtained from the relevant literature. The Clinical 
Outcome Assessment in Surgical Trials of Limbal Stem cell deficiency [COASTL] tool, as 
developed by Shortt and coworkers, could be used to assess the efficacy of our novel method 
on recipient corneas.40 This method grades limbal stem cell deficiency and the response to 
treatment with ex vivo cultured limbal epithelial stem cells on a macroscopic and numerical 
basis.40 Corneal haze, epithelial irregularity, epithelial defects and vascularization are graded 
using this method.40 
Shimmura and Tsubota mention that the next several years may see a paradigm shift in the way 
LSCD patients are treated.35 They state that cultivated sheets may be used as temporary grafts 
for acute phase LSCD, or perhaps for optical surgery to be repeated every several years.35 They 
also mention that epithelial sheets may be engineered from ectopic epithelium (as is planned in 
our research project) or from stem cell banks.35 They concluded with the following statement, 
‘Because randomized controlled studies are difficult under these circumstances, we completely 
agree with the concluding remarks by Cauchi and associates suggesting the need for a register 
to pool standardized data from several centers specializing in the treatment of severe ocular 
surface disease.’ 35 
This emphasizes the importance of performing corneal stem cell research at Groote Schuur 
Hospital, and reporting on our experience. These results will then contribute towards a register 
to pool standardized data globally.  
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This study will help to provide further details for optimal culturing conditions in our setting and 
to refine our culturing technique. Eventually we will be able to transplant epithelium on to 
limbal deficient corneas with the necessary ethical approval. The long term goal of this research 
would be to construct a cornea consisting of ex-vivo cultured epithelium, endothelium and 
stroma. Due to the severe shortage of corneal tissue in South Africa as well as globally, this 
could help to reduce the demand for corneal tissue from cornea banks globally. Ultimately ex-
vivo cultured corneal tissue will reduce waiting times for corneal transplants, particularly in 
Africa. The ultimate goal of this research will be to improve patient care in South Africa for 




An observation of our research was that bacterial growth was absent from cultures, even 
though topical antibiotics were not applied in cultures. The researchers assume that this is due 
to the use of prophylactic systemic antibiotics in donor patients. We would like to postulate 
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ABSTRACT 
Purpose/Aim of the study: To assess if corneal epithelium can be cultured ex vivo from corneas eviscerated 
due to irretrievable trauma, according to a cell cultu re method that made use of autologous platelet-rich 
plasma (A-PRP) as culture substrate. To compare corneal epithelium cultured ex vivo from corneas eviscer-
ated following trauma using A-PRP combined with Dulbecco's modified Eagles medium (DMEM), versus 
DMEM alone. 
Materials and methods: This was a laboratory case-controlled study of human corneal cells cultured in a 
mixture of A-PRP and DMEM, versus DMEM alone from six eviscerated corneas. A 100 explants were created, 
of which 50 explants were plated on A-PRP-gel construct combined with DMEM and 50 controls were placed 
in serum-free DMEM alone. Donor patients received systemic antibiotics prior to evisceration. 
Results: Confluent epithelium in monolayers could be cultured when donor limbal biopsies were placed in a 
mixture of A-PRP culture medium and DMEM. No growth was observed when corneas were placed in serum-
free DMEM medium only (p < 0.05). No bacterial infection was observed in cultures. 
Conclusions: This study demonstrated that A-PRP is a viable and effective alternative to bovine serum for the 
ex vivo expansion of limbal epithelial cells. It also shows that eviscerated corneas are a viable source of donor 
tissue for this purpose in South Africa where access to tissue banks is limited. 
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rich plasma; no animal 
products 
Introduction 
Donor corneas are too scarce for the culturing of corneal 
epithelium to be efficiently rolled out in South Africa. The 
authors therefore utilized fresh corneal tissue in patients who 
have obtained irretrievable damage to thei r corneas and 
required eviscerations, since this was more readily available, 
and then developed a resource-based protocol devoid of ani-
mal products, to culture corneal epithelium from. These evis-
cerated corneas would normally be discarded. 
with stem cell defic iencies such as are seen in chemical burn 
wounds, SJS, and in ocular cicatricia l pemphigoid, where 
visual acuity can improve up to two or more lines post 
transplantation.5•6•7•8 
Corneal trauma is common in South Africa. Du Toit et al. state 
that there were 249 open globe injuries over a 2-year period at 
Groote Schuur Hospital, o f which 24.5% required eviscerations. ' 
Around 64.9% of these patients with open globe injuries were 
younger than 35 years of age. 1 
The management of limbal stem cell deficiencies of the cornea 
remains a big challenge in South Africa, due to the prevalence of 
the human immunodeficiency virus (HIV), which is 11 %.2 HIV-
positive patients may present with Stevens-Johnson Syndrome 
(SJS) due to anti-retroviral medication (ARV) and patients with 
SJS have a 20% risk of serious eye manifesta tions.3'4 In our setting 
SJS associated with anti-retroviral therapy is the leading cause of 
limbal stem cell deficiency. 
It has become accepted practice in the developed world to 
transplant cultured epithelial limbal stem cells onto corneas 
In our study we investigated (i) the use of a culture med-
ium that contained autologous p latelet-rich plasma (A-PRP) 
as a culture substrate for corneal epithelial cell generation, 
obviating the need for 3T3-feeder fib roblasts an d (ii) the 
viability of using eviscerated corneas, which are unfit for 
transplant, to culture epithelium from limbal explants. 
Materials and methods 
Ethical considerations 
The study was approved by the Groote Schuur Hosp ital Ethics 
committee and adhered to the principles of the Declaration of 
Helsink i o f 1964. Patients could withdraw from this study at 
any stage. 
Study subjects 
The participants in this study were six males with a m ed-
ian age of 28 (range 21- 65). Two cases were HIV posit ive. 
CONTACT Leonard G. Heydenrych O flutedr@gmail.com ~ University of Cape Town, Division of Ophthalmology, Groote Schuur Hospital, Observatory, Anzio 
Road, Cape Town, 7925, South Africa. 
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/ icey. 
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Patients received int ravenous cefazolin and oral ciproflox-
acin preoperatively on admission. 
Clear guidelines for the indication of evisceration were 
followed, which included (i) no perception of light, (ii) gross 
damage to an eye due to trauma not salvageable with suturing, 
(iii) total afferent pupillary defect, and (iv) auto-eviscerated 
eye following trauma. 
Corneal harvesting 
Limbal corneal stem cells were obtained from six corneas 
harvested from eviscerated eyes at the Division of 
Ophthalmology of Groote Schuur Hospital. Patients received 
blood tests prior to harvesting, which included Hepatitis B 
and C, HIV, and Syphilis serology. 
Corneas were excised in theatre, during evisceration, with at 
least a 2 mm rim of sclera and stored in Optisol solution. After 
harvesting, corneas were kept at room temperature and deliv-
ered to the Department of Anatomy of the University of 
Stellenbosch. Corneas were accompanied by 8 ml of the 
patient's venous blood in REGEN PRP0 blood-collection tubes. 
Laboratory processing and limbal epithelial cell culture 
Tissue cultures were set up within 12 hours of arrival at the 
laboratory. Venous blood was collected from the same corneal 
donor; 8 ml of venous blood was injected into a REGEN Lab-
sterile THT glass tube containing an anticoagulant (REGEN Lab- , 
Switzerland). Venous tubes were centrifuged at 4000 revolutions 
per minute (rpm) and plasma was separated from red blood cells 
above the buffy layer. Platelet-rich plasma (PRP) was aspirated, 
activated with calcium chloride, and 2ml aliquots used to coat the 
base of each sterile petri-dish, the procedure being conducted 
aseptically in a vertical-type laminar flow hood (Labotec-, Cape 
Town). Gel formation occurred within a few minutes after PRP 
activation with calcium. 
Corneas were carefully orientated on a glass tablet and 
diced into explants containing cornea and limbus, devoid of 
donor conjunctiva, and measuring about 2 x 2 mm. Careful 
clearance of conjunctiva and excess sclera was important to 
avoid competitive overgrowth with conjunctiva! epithelium 
and fibroblasts.9 Six-well petri dishes were used and each 
explant was suspended in PRP gel and matched with an 
explant in serum-free Dulbecco's modified Eagles medium 
(DMEM) in an adjacent well (control). 
Explants were placed in PRP with the epithelial surfaces facing 
upward. One drop of DMEM, not supplemented with fetal-calf 
serum, was placed on each explant with a pasteur pipette within 
the laminar flow hood. No antibiotics were used in cultures. 
Control explants without PRP base were placed epithelium side 
up on the inside base of petri dishes and each explant was covered 
with one drop of serum-free DMEM. The two sets of petri dishes, 
PRP-coated and PRP-free plates, were placed in a sterile Nuaire- , 
carbon dioxide (CO2) , HEPA-incubator-. Epithelial cell prolifera-
tion was conducted in an atmosphere of 95% oxygen and 5% CO2 
throughout the study at 37°C. DMEM was changed three times a 
week in PRP and PRP-free control cultures. 
Cultures were inspected three times weekly under an 
Olympus- GX41 inverted phase-contrast microscope. Digital 
Figure 1. Epithelium (blue arrow) is seen expanding from the "hill" or forming 
face (red arrow). 3D Proliferation is demonstrated here where the "hill" is out of 
focus due to proliferation in the vertical axis, whereas the "valley" is in focus, 
representing epithelium in a hor izontal layer. 
images of monolayers and cell clusters were captured with a 
Sony- combination Carl-Zeiss- camera at 7.2 megapixels. 
Inverted microscopic digital photographs at magnifications 
of 100 times and 200 times were taken at weekly intervals to 
monitor the growth of cultured monolayers. Cell dynamics 
and cell proliferation on the forming and maturing face of the 
monolayers were photographically recorded and counted 
using a micrometer and eye-piece grid, which were focused 
on explants (see Figure 1). Cell locomotion (speed of migra-
tion) was reviewed at 6 weeks and assessed daily by an 
inverted transmission microscope. 
For the purpose of this study we confi rmed the character-
istics of epithelium by means of its characteristic three-dimen-
sional morphological in situ appearance on high-resolution 
inverted phase-contrast microscopy as did Shimazaki et al.8 
Epithelial cell counts were determined on a hemocytometer 
cell-counting chamber (Neubauer- ) and viable cell staining 
was achieved applying 0.4% trypan blue solution and viewing 
cells at 100 times magnification (Zeiss- ). Enhancement was 
selectively applied with the use of a Zeiss Image Analyser-
wi th specification written macroprogram. Nonparametric, 
descriptive statistics were selected (Mann-Whitney U test) 
to compare the two types of tissue-culture parameters evalu-
ated, those in PRP and those without PRP. Results were 
considered statistically significant if p < 0.05 for that 
parameter. 
Immunofluorescent staining was observed through a dark-
fie ld inverted microscope. K3 and Kl2 staining were per-
formed with monoclonal antibodies, obtained from Gen 
Way Biotech Inc. A standard technique was used as recom-
mended by the manufacturers. Histological analysis of the 
epithelium was also performed. 
Results 
At day 21 corneal explants were surrounded by a clear lucid 
area in the PRP substrate, which represen ted an epithelial cell 
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Figure 2. The corneal explant (blue arrow) is surrounded by a lucid area of 
epithelium (red arrow) in PRP. 
prolife ration zone (see Figure 2). Epithelium was confirmed 
by means of phase contrast microscopy, histological studies, 
and immunostaining. Epithelial proliferation was only noticed 
in dishes containing PRP. Success was classified as the gen-
eration of at least one complete monolayer of cells ex vivo on 
a substrate. Growth disc sizes of 9 x 9 mm, 9 x 10 mm , and 9 
x 12 mm could be cultured in the platelet-rich gel. 
Primary cultures were not established in dishes consisting of 
DMEM alone (p < 0.05). Visible, proliferating cells were con-
firmed by inverted microscopy and trypan-blue staining on day 
4 in PRP-based culture in all six wells. On day 14 epithelial cells 
formed a confluent monolayer of cells, sin1ilar to that reported by 
Shin1azaki.8•9 Primary cultures consisting of confluent 15 mm-
diameter multilayered epithelium were established in 70- 80% of 
PRP cultures by day 21. Cultures were devoid of conjunctiva! 
epithelium and more than 80% of cells were viable with trypan-
blue test staining. Occasional fibroblasts were morphologically 
identifiable. 
Mid-corneal epithelium proliferated at 0.47 mm/day and lim-
bal-based epithelium at 0.59 mm/day. Growth at the limbus was 
faster than elsewhere in the cornea (p < 0.05) and slowest at the 
center of the cornea. When present, corneal fibroblasts commu-
nicated through strands with each other. 
Phase contrast microscopy 
Phase contrast microscopy revealed small round cells of two or 
more layers as described by Shimazaki et al., which were flat with 
no papillary structures.8•10 These cells were squamous and cuboi-
dal with prominent nuclei and d ear cell borders and had the 
appearance of epithelial cells (see Figure 3 ). On low magnification, 
epithelium was seen proliferating in an "anticlockwise nebula" 
around the explant. 
Histology 
Donor cultured corneal monolayers were confirmed as epithe-
lium after being stained with hematoxylin and eosin (H&E) at 
CURRENT EYE RESEARCH @ 3 
Figure 3. Epithelium (red arrow) is seen proliferating in a monolayer from the 
limbus (blue arrow). 
200x magnification as performed by several other researchers6•8 
(see Figure 4). The epithelium was confluent, squamous, regular 
hexagonal cells of cuboidal appearance, and cell borders were 
clearly demarcated.6' 11' 12 
lmmunostaining 
Cells were confirmed as epithelium by means of K3 and Kl2 
staining.5•13 Keratin expression was confirmed by immune stain-
ing of cultured corneal epithelial cells with cytokeratin 3 and 
cytokeratin 12 monoclonal antibodies (GWB-4E84CO, Gen Way 
Biotech Inc., USA). 
Figure 4. Hematoxylin and eosin (H&E) stain demonstrating squamous epithelial 
cells at the proliferating edge (green arrow). Notice the dense configuration of 
epithelial cell nuclei at the proliferating edge (blue arrow). 
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Discussion 
The key findings of this study are that epithelium could be 
cultured from eviscerated corneal tissue and that epithelial 
growth could only be initiated from corneas placed in auto-
logous PRP. 
Our culture method differs from conventional methods used 
by other researchers such as Pellegrini et al., Rama et al., and 
Koizumi et al., since we did not use any animal products, such as 
fetal-calf serum, mouse-derived irradiated fibroblasts, or amnio-
tic membrane in our cultures.5' 14' 15 Traditional methods used 
irradiated fibroblasts, which surrounded the explants, to initiate 
epithelial growth by releasing growth factors.5 This method is 
currently still used worldwide since the 1980s and no adverse 
effects have been reported. 14 Media containing anim al products 
unfortunately have the risk of transmitting zoonotic infections.6 
Although cultures by Shortt et al. and Shimazaki et al. did not 
contain any irradiated 3T3 feeder fibroblasts, Shortt et al. used 
10% irradiated fetal bovine serum, and Shimazaki et al. used 
denuded amniotic membrane.8' 11 Di Girolamo et al. moved 
away from the traditional culturing method as set out by 
Pellegrini et al. and only used autologous serum as culture 
medium, but combined with topical antibiotics, to culture 
epithelium on to contact lenses. 15' 16 Researchers usually add 
antimicrobials containing penicillin, streptomycin, and ampho-
tericin B. 5•8•11 We did not use any antibiotics in our cultures, and 
only used PRP as the culture medium. Our patients did receive 
systemic antibiotics before harvesting. 
Shortt et al. mention that corneal epithelium can be cul-
tured using an "explant culture system" or a "suspension 
culture system".17 W e used th e explant system by placing 
the limbal biopsy (epithelium and limbus) directly in the 
culture medium consisting of autologous, donor-specific 
A-PRP gel. The advantage of this method is that limbal 
epithelial stem cells are not disrupted, but retained within 
their anatomical microenvironment during culture, which 
may favor the efficient formation of colonies of the 
epithelium. 18 The adhesive nature of fibrin in plasma also 
enables transplanted epithelial sheets to be attached without 
sutures, following which the fibrin matrix naturally degrades.18 
Satake et al. state that a carrier-free method of transplanting 
cultured epithelium could lead to better graft survival, less 
postoperative neovascularization, and better visual acuity.7 
Our culture method was devoid of amnion and consequently 
was carrier free. 
Shortt et al. also describe a suspension culture method to 
separate epithelium from stroma by means of dispase, fo llowed 
by the addition of trypsin to create an epithelial cell suspension, 
which is then placed into culture medium.11' 17 Cells were seeded 
onto amniotic membrane and cultured at 37°C in a humidified 
incubator with 5% CO2 in air, as were done in our research, 
although we did not use amniotic membrane.5' 11 We did not 
disrupt the epithelium by means of enzymatic modulation. 
Our culture method aimed at minimizing exposure to toxic 
products and zoonotic products. The risk of the transmission of 
animal viruses and prions is eliminated in our culture method, 
should the initial limbal biopsies be clear of any disease. The 
patient's own venous blood was collected to generate A-PRP gel. 
In our experience the optimal culture period when the mono-
layer was optin1ally dense was between 15 and 21 days. The graft 
became too thick and became detached form the fibrin scaffold 
after 21 days. Koizumi et al. state that they used a 4-week culture 
period.5 
In most cases the fibrin biological construct formed a 
thickened, prolifera ting edge on average consisting of epithe-
lium (95%) and fibroblasts (5%), followed by a thin layer of 
epithelium (see Figure l ). In most cases the epithelium pro-
liferated concentrically around the explant with cells expand-
ing from the "hill" or "edge" of the explant toward the 
periphery of the PRP. 
Du Toit found that fibroblasts proliferate at about the same 
speed as corneal keratinocytes, but that eventually at 6 weeks, 
fibroblast overgrowth occurs.9 Once epithelial monolayer for-
mation occurs, fibroblasts become less prominent and in the 
minority.9 The authors assume that this is because suffic ient 
fibroblast growth factors have already been produced by nat-
ural fibroblasts instead of lethally irradiated fibroblasts, to 
stimulate epithelial growth. 
Shimazaki et al. and Pellegrini et al. performed a histologic 
examination using H&E staining and Shimazaki et al. 
examined tissues with phase microscopy, as were performed in 
our study.8•15 Epithelium stained for K3, which indicated corneal 
epithelium.15•19•20 We performed both K3 and Kl2 staining with 
monoclonal antibodies. The cultured epithelium displayed a 
corneal phenotype through the process of immunostaining, 
which used antibodies against cytokeratins K3 and Kl2.19 
According to Shermer et al., the 55K acidic (HKI2) and 64K 
basic (HK3) keratins indicate a "corneal-type" differentiation.10 
K3 and Kl 2 keratins are located supra-basally in the corneal 
epithelium as well as in the limbus, but Shermer et al. state that 
the central corneal epithelium stains uniformly including basal 
cells for HK3, whi le the lirnbal epithelium stains supra-basally 
for HK3. 10 Our epithelial cultures stained uniformly for K3, 
which indicated basal cell staining and confirmed that cultures 
were older than 15 days and corresponds with the statement by 
Shermer et al. that supra-basal staining is not an absolute 
C K3 . . 10 requirement ,or stru.rnng. 
PRP contains up to 4.4 times more platelets than whole blood, 
usually more than 200,000 platelets/µI and contains all compo-
nents of whole blood.21.22 It can be produced by many commercial 
systems and in our research we used the REGEN°-PRP system.9.22 
Mazzucco et al. showed that REGEN displayed a higher recovery 
of transforming growth factor beta (TGF-~), basic fibroblast 
growth factor (b-FGF), and insulin-like growth factor 1 (IGF-1) 
and the highest amount of growth factors, compared to other PRP 
gel preparations, but REGEN had lower platelet concentrations, 
nl if . 1 22 probably due too y one centr ugallon s ep. 
After centrifugation of the whole, anticoagulated venous 
blood sample the buffy layer of white blood cells is situated 
just above th; densely packed red blood cells.21 The platelets 
are at its highest concentration just above the buffy layer, and 
21 it is this layer that we use to generate autologous A-PRP. 
This differs from the autologous serum, which has been used 
by researchers such as Di Girolamo et al. and Nakamura et al. 
as culture medium, where whole blood after being centrifuged 




PRP typically contains three to five times more growth 
factors than baseline, which are responsible for cellular 
proliferation.2 1'23 The alpha granules in platelets and in PRP 
release platelet-derived growth factor (PDGF), TGF-~l, vas-
cular endothelial growth factor (VEGF), b-FGF, and epider-
mal growth factor (EGF).2°·2 1 Calcium, which leads to gel 
formation of PRP, also enhances cell proliferation and is 
beneficial to the release of PDGF.9•24 
In the literature, cadaver corneas or limbal biopsies are 
used to culture ex vivo epithelium.15 The South African situa-
tion creates the opportunity to culture ex vivo epithelial cells 
from severely damaged corneas due to trauma. These corneas, 
which are usually discarded following evisceration, have in 
our experience proven to be a useful source for epithelial cell 
proliferation. In none of the six cases observed was the pene-
trating corneal trauma obtained, sufficient to prevent epithe-
lial cell proliferation. Eviscerated corneas were used in our 
setting to establish our culture method. Clinicians following 
this method for transplantation purposes should make certain 
that donors have no blood-borne diseases, are HIV negative, 
and not in the window period of HIV. This same culture 
technique can now be used to culture epithelium from living 
related donors or from the contralateral eye of a patient with 
limbal stem cell deficiency. 
We postulate a new method for culturing corneal epithe-
lium by the application of donor-specific A-PRP-gel, devoid 
of any animal products, antibiotics, amnion, or irradiated 
feeder fibroblasts. This approach may well improve the safety 
of cell cultures if eventually destined for human application. 
Conclusion 
To our knowledge, this is the first study to establish the growth 
pattern, cellular proliferation, and characteristics of epithelium 
cultured from eviscerated corneal tissue. In our experience, trau-
matized eviscerated corneas render successful epithelial growth. 
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Eviscerated Corneas as Tissue Source for Ex Vivo Expansion of Limbal Epithelial Cells on 
Platelet-Rich Plasma Gels: Reviewing the ex vivo growth pattern and characteristics of 
cultured corneal epithelium in platelet-rich plasma gels. 
Aim of Study: To establish if epithelium can be cultured from corneas eviscerated due to 
severe trauma. 
Full ethical approval was obtained from the ethics committee of Groote Schuur Hospital 
(February 2010).  
 
Summary 
 Corneas will be harvested from patients consenting for evisceration due to the history of 
trauma with irretrievable loss of vision and no perception of light. 
 These patients will present with an afferent pupillary defect as well as irreparable 
damage to the normal architecture of the eye. 
 Patients will sign informed consent for above mentioned procedures to be performed. 
 Consent for evisceration will be obtained by at least two clinicians not participating in 
this research project. 
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 Patient information sheets in three official languages will be provided to patients 
explaining the full extent of this research project.        
 Consent to participate in this research project will be obtained on specially designed 
consent forms, as indicated in this protocol. Consent will also be obtained from patients 
for storage of human tissue. The second page of the consent form will be initialed by the 
patient. 
 Corneas will be stored in normal saline and transported to the laboratories of the 
Department of Anatomy of the University of Stellenbosch, where optimal conditions 
reside for the culture of corneal cells under the directorship of Professor D. F. du Toit. 
 Patients will receive blood tests prior to the donation of their eviscerated corneas, 
which will include Hepatitis B and C, HIV, and Syphilis serology. Standard protocol will be 
followed in obtaining consent for HIV testing. 
 20 milliliter blood will be collected from each corneal donor and centrifuged to create 
platelet-rich plasma (PRP).  
 Limbal stem cells will be obtained from the donated corneas through the process of 
button biopsies and micro-dissection of each cornea. 
 Corneal explants will be plated in PRP gel.  
 Cells from each patient’s cornea will be kept separately, and cultured separately from 
other patient’s corneas. 
 The researchers will attempt to culture cells from approximately five to ten corneas. 
 Epithelial cell growth will carefully be monitored by means of phase contrast microscopy 
and photographs of cultured cells at seven day intervals. 
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 Success will be defined as the growth of at least one monolayer of cells on a substrate. 
 Corneas and epithelium will be stored for the duration of this research project and 
consent for storage will be obtained from patients.  
 The results obtained will contribute towards the MMed dissertation of Dr. Leonard G. 
Heydenrych, under the directorship of his MMed promoter, Dr. N. Cockburn.1  
 The clinical research supervisor for this study will be Professor D. F. du Toit, FCS (SA), 
FRCS (Ed), PhD (Stell), D.Phil (Oxon), FICA (USA), a researcher who has published 
extensively in the field of molecular biological engineering.2 
 The data obtained during this research will be reported at a national congress and the 
paper will be submitted for publication in a peer reviewed journal.3  
      
Clinical Application 
Through the process of harvesting, limbal epithelial stem cells may be obtained and used to 
produce corneal epithelial cells ex vivo or outside the human body, through the process of 
biological engineering.1,2,3,4 Corneal stem cells may also be harvested from damaged or 
traumatized corneas, since only a small portion of the limbus is required to culture new cells. 
Due to the very high incidence of irreparably damaged corneas following trauma, we have a 
vast source of limbal stem cells in South Africa.5 Corneas which have to be eviscerated due to 
trauma, may now also be used as a source of limbal stem cells to culture corneal epithelium 
                                                          
1
 Dr. N. Cockburn resigned from UCT in 2011 and is consequently not my internal supervisor anymore.   
2
 Please see attached CV of Prof. D.F. du Toit.  
3




from. We would like to see if we can successfully cultivate corneal epithelial cells from corneas 
obtained from irreparably damaged eyes that are being eviscerated as part of standard care.   
Ocular surface problems such as infective corneal ulcers and chemical burns of the eye may also 
lead to persistent epithelial defects, not responding to treatment. This may ultimately lead to 
vascularization and perforation of the cornea. Blood vessels tend to grow over epithelial 
defects, leading to opacification of the cornea and the loss of vision. These defects may also 
perforate and lead to the development of devastating infection of the eye, called 
endophthalmitis. If not treated promptly with intravitreal antibiotics, this could lead to 
blindness. Limbal stem cell deficiency as a potential cause for corneal decompensation and 
corneal perforation may be managed by the transplantation of ex vivo cultured epithelium. 
 
The benefit of ex vivo transplantation of limbal stem cells 
Limbal stem cell transplantation may reduce inpatient stay in hospital wards and will also 
reduce the risks of opacification and perforation of the cornea. Inevitably this will reduce the 
burden on our over full wards and will also lead to considerable financial savings for the state 
sector, since inpatient stay will be shorter. 
Traditionally, patients with persistent epithelial defects require a much longer stay in hospital 
due to the chronicity of these defects, compared with other ophthalmological conditions. These 
defects are usually treated with topical antibiotics, vitamins, progesterone and tetracycline and 
monitored daily in a ward. These defects may also be covered with a bandage contact lens or 
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with amniotic membrane, in an attempt to accelerate healing and prevent perforation.6 The 
natural growth factors present in amniotic membrane tend to accelerate healing of these 
defects as well.6  
Researchers have attempted to transplant limbal allografts onto diseased eyes in an attempt to 
replenish the source of epithelial cell formation.7 This has been achieved with different degrees 
of success. Due to the risk of graft rejection, limbal allograft transplants carry the burden of 
continuous immunosuppression. The procedure is also technically difficult and is dependent on 
the availability of corneal grafts. Currently the waiting list for corneal grafts in South Africa is 
approximately two years.  
Lately researchers have attempted to transplant corneal cells onto amniotic membrane.2,3,7 The 
cells were cultured ex vivo from corneal limbal cells, which were harvested from donor 
corneas.2,3,7 These membranes with cells were then transplanted onto corneas with limbal stem 
cell deficiency.2,3,7,8 Currently these transplants have shown the most promising results and this 
method is also far less invasive than limbal stem cell allografts, which involves the transplant of 
a full thickness circular piece of sclera including the limbal epithelial stem cells.7 The advantage 
of transplanting ex vivo expanded stem cells rather than keratolimbal or conjunctivolimbal 
transplants is that this novel method is less invasive and that rejection and immunosuppression 
are less likely.7 Defects have recovered fully without corneal scarring and without the loss of 
vision.2 These methods of transplantation have not been attempted on the African continent as 
yet. We feel that this form of transplant can greatly improve the current management of our 
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patients and can prevent the loss of vision in patients with limbal stem cell deficiency, awaiting 
corneal transplants.   
 
Method 
We will be obtaining corneas from eyes with irretrievable loss of vision, which had to be 
eviscerated following severe penetrating eye trauma and the consequent risk of sympathetic 
ophthalmia developing.9   
The corneas will be surgically removed from the eviscerated eyes and stored in normal saline 
and kept below 7 degrees Celsius. The corneas will be excised during the procedure of 
evisceration. This will include the excision of the cornea with at least a two millimeter rim of 
sclera. Only eyes with irretrievable damage will be eviscerated. This will be performed by 
surgeons other than the surgeons involved in this research project. Clear guidelines for the 
indication of evisceration will be followed by the appropriate surgeons performing the 
eviscerations.  
A standardized method for cultivating corneal epithelial cells will be used as established by 
Professor D.F. du Toit, from the Medical Research Council and obtained from the relevant 
literature.2,3,8  
Limbal corneal stem cells will be grown from corneas harvested from eviscerated eyes with 
irretrievable sight-loss. The reason for evisceration will only be due to irreparable damage 
sustained by trauma in an eye with no perception of light. These patients will give written 
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informed consent for corneal harvesting which will then take place during evisceration. A 
separate consent form will be signed for this purpose and consent will be obtained by at least 
two eye surgeons. This will be additional to consenting for the primary procedure of evaluation 
under anaesthetic and evisceration. Patients will also receive blood tests prior to harvesting, 
which will include Hepatitis B and C, HIV and Syphilis serology. Patients will give written 
informed consent for HIV testing according to standard protocol and will receive pre- and post-
test counseling by a social worker. Any patients testing positive for HIV, Syphilis or Hepatitis, 
will be informed of the results and will be referred for further management of these diseases. 
Patients receiving pre-test counseling and who are not willing to receive the outcome of their 
blood tests will be excluded from this research.  
Blood will also be obtained from each patient to create autologous platelet-rich plasma (A-PRP) 
to extract the necessary growth factors to promote corneal cell proliferation for each individual 
case.10,11,12    
Patients will be fully counseled before signing consent for evisceration by two clinicians not 
participating in this research project. Patients will receive information about the indication, 





Indications for evisceration: 
 No perception of light. 
 Gross damage to an eye due to trauma, not salvageable with suturing. Not removing 
such an eye with the patient’s consent, will expose the patient to the risk of sympathetic 
ophthalmia, which could lead to the loss of vision in the normal fellow eye.9 
 Full afferent pupillary defect. 
 Auto-eviscerated eye following trauma. 
 Consent from the patient for the evisceration to be performed. 
The eye will only be eviscerated if the patient complies with all of the indications as set out 
above.    
The corneas with the associated blood samples will then be transported to the laboratories of 
the Department of Anatomy of the University of Stellenbosch, for the sole purpose of molecular 
biological engineering with the consequent growth of corneal epithelial cells. Prior to this a 
short letter will have to be issued by the Departmental Head of Ophthalmology at Groote 
Schuur Hospital to state that he/she approves of the transport of discarded tissue and blood 
samples to the research laboratories at the Department of Anatomy of the University of 
Stellenbosch.4 This letter will also be provided to the Inspector of Anatomy at the University of 
Stellenbosch to state that the appropriate researchers have received donated tissue that was 
discarded from patients at surgery because of irretrievable sight-loss. The written ethical 
approval from the University of Cape Town and the protocol number will also be required. A 
                                                          
4
 See letter by Prof. Colin Cook attached. 
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letter will also be provided by Prof. Colin Cook, Head of the Department of Ophthalmology at 
Groote Schuur Hospital, to state that he approves of the collaborative research.  
The corneas will be accompanied by the signed informed consent form of the patient stating 
that his/her cornea may be used for culturing corneal cells. The corneal epithelial cells will be 
cultured under supervision of Prof. D. F. du Toit. He has given permission for this research to 
proceed and to be performed at his laboratories at the Tygerberg Medical Campus where 
optimal infrastructure is residing for biomedical engineering of corneal stem cells. 
During this research project the corneas and cultured cells will be studied microscopically and 
immuno-histologically and will not be used for transplantation purposes. The corneas and 
grown stem cells will not be used for any form of financial gain whatsoever. Publications may 
come from above-mentioned research with the appropriate mentioning of all the participants 
in this study. 
The research, under directorship of me and Prof. D. F. Du Toit, will aim to establish the growth 
patterns of cultured epithelial cells as well as the media best suited for epithelial cells to grow 
upon. Epithelium will be identified morphologically by means of microscopy as well as 
immunohistochemistry.  
What makes this study unique is the fact that corneal cells will be grown from freshly 
eviscerated corneas, and not from cadaveric corneas or limbal biopsies as done in previous 
research.2,3,7,8 The media which will be explored will include fresh amniotic membrane, 
biodegradable membrane, fibrin, as well as contact lenses.      
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Limbal stem cells obtained from harvested corneas will thus be cultured ex vivo in appropriate 
culture media. The most suitable transport media and carrier media for the cultured stem cells 
will also be established during research. Culture media will be provided by the University of 
Stellenbosch and amniotic membrane will be provided by the Division of Ophthalmology of the 
University of Cape Town.  
The study design will represent a case series of five to ten cases of cultured corneal cells. The 
setting will be the Division of Ophthalmology of Groote Schuur Hospital, Cape Town, South 
Africa and the laboratories of the Department of Anatomy of the University of Stellenbosch. 
The subjects for this study will be selected on the basis of the inclusion and exclusion criteria as 
follows. Outcome measures will demonstrate the growth and success of cultured corneal cells 
by using freshly eviscerated corneas for culturing purposes.    
Exclusion Criteria 
 Patients not willing to partake in the study. 
 Patients not willing to sign informed consent.  
 Patients not willing to receive the outcome of their blood tests. 
 Patients not qualifying for evisceration. 
 Patients not exposed to eye trauma. 
Inclusion Criteria 
 Patients qualifying for evisceration.  





Literature review:  May 2009 to December 2009 
Protocol development: July 2009 to February 2010 
Record retrieval and data capturing: February 2010 to February 2011 
Analysis of results: March 2011 
Writing of paper for submission to peer reviewed journal: March 2011 to September 2014 
 
Budget 
Assistance from the Department of Ophthalmology of the University of Cape Town and the 
Department of Anatomy of the University of Stellenbosch. 
 
Communication 
Reporting and implementation. 
This project may be submitted as a dissertation for a Masters degree (MMed), reporting on a 
pilot study of five to ten cases of ex vivo cultured corneal epithelial cells, cultured from 




Alternatively the results will be reported at a local congress (OSSA, March 2011) and the paper 
will be submitted for consideration for publication in a peer reviewed ophthalmic journal.  
The results of this study will assist to register a pool of standardized data on culturing corneal 




The results will be presented to a large degree without any statistical analysis and will mainly 
report on the success of growth of corneal epithelial cells, cultured from eviscerated donor 
corneas on a fibrin scaffold. Several microscopic digital photographs will be taken at weekly 
intervals to monitor the growth of cultured cells. The different monolayers achieved during 
culturing will be closely monitored and photographed. Culturing of epithelium from patients 
with blood borne diseases will not be excluded from this study and their epithelial growth 
patterns will be observed compared to healthy patients.  
Success will be classified as the growth of at least one monolayer of cells on a substrate. Should 
six layers of epithelial cells be established, this could closely represent the architecture of the 
normal human corneal epithelium. The confluence of layers of cells will be monitored as well as 
the smoothness achieved of superficial layers of cells. These cells with their connections will be 
photographed by phase contrast microscopy.14 
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Declaration of Helsinki 
September 2010 
 
To whom it may concern 
I hereby declare that the research conducted in this study, namely: 
 
Eviscerated Corneas as Tissue Source for Ex Vivo Expansion of Limbal Epithelial Cells on 
Platelet-Rich Plasma Gels: Reviewing the ex vivo growth pattern and characteristics of 
cultured corneal epithelium in platelet-rich plasma gels, 
 
adheres to the ethical principles for medical research as set out in the declaration of Helsinki 
of the World Medical Association (59th WMA General Assembly, Seoul, October 2008). 
 
Yours faithfully 
Dr Leonard G Heydenrych 
Division of Ophthalmology 
Groote Schuur Hospital, University of Cape Town 
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Patient Information Sheet and Consent Form 
 
Patient Information Sheet: Corneal stem cell growth 
 February 2010 
Dear Patient 
Many thanks for being willing to partake in this research project. As you are aware, your 
surgeon has explained to you that your eye has to be removed surgically due to the severe 
damage that it obtained during your accident and the risks involved in not removing it. We 
would like to ask your permission to use your cornea, which would usually have been discarded, 
for research purposes.   
Research has shown that it is possible to artificially grow new cells from the existing cells of the 
cornea. We as researchers will try to grow cells from your discarded cornea. The cornea has a 
group of cells situated at the corneal limbus, which have the inherent ability to multiply and 
produce normal corneal cells. We will make use of this ability of your corneal cells, by placing 
them in special solutions in laboratories and observing their growth. This will help us to 
understand how corneal cells can grow outside the body. This is a very exciting new 
development, since new treatment modalities are now possible!  
We can e.g. use these cells to close big corneal defects and improve healing. Please note that 
you will also be requested to agree/disagree that your cornea and stem cells may be stored for 
an indefinite period of time for further research. Hopefully one day, we might even be able to 
grow complete corneas through these methods and transplant them!   
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Many thanks for allowing us to use your discarded cornea for this research project. Please note 
that none of these corneas or cells will be used for any financial gain whatsoever!  
Please feel free to contact me on speed dial 76622 or telephone 021 404 3525, should you have 
any questions regarding the use of your cornea. You are also welcome to contact the Research 
Ethics Committee, as indicated below. 
With thanks 
Dr Leonard G. Heydenrych 
Division of Ophthalmology 
UNIVERSITY OF CAPE TOWN  
Faculty of Health Sciences 
Research Ethics Committee 
E52- 23 Old Main Building, Groote Schuur Hospital, Observatory, 7925 







Pasiënt Inligtingsvorm: Korneale stamselnavorsing 
Februarie 2010 
Geagte Pasiënt 
Baie dankie vir u bereidwilligheid om aan hierdie navorsingsprojek deel te neem. Soos u deeglik 
bewus is, het u chirurg aan u verduidelik dat u oog verwyder moet word, vanweë die erge skade 
wat u oog opgedoen het tydens u ongeluk. U chirurg het ook verduidelik dat daar in u geval 
risikos aan verbonde is indien u oog nie verwyder sou word nie. 
Ons wil graag u toesteming vra om u kornea, wat gewoonlik wegdoenbaar sou wees, te gebruik 
vir navorsings-doeleindes. Navorsing het getoon dat dit moontlik is om kunsmatig nuwe selle te 
kweek van die bestaande selle van u kornea. Ons as navorsers wil poog om nuwe korneale 
stamselle van u kornea te kweek. Die kornea bevat n groep selle wat geleë is by die korneale 
limbus, wat die inherente vermoë besit om te vermeerder en om normale korneale selle te 
vorm. Ons wil graag van hierdie biologiese vermoë van u kornea gebruik maak, deur u limbale 
korneale selle in laboratoriums te laat vermeerder in chemiese oplossings buite die liggaam. 
Ons behoort meer te leer oor die wyse waarop korneale stamselle groei deur u selle te 
observeer. Hierdie wyse om selle buite die liggaam te laat groei, is n opwindende nuwe 
ontwikkeling, wat baie nuwe behandelings-modaliteite kan laat ontvou! Ons kan byvoorbeeld 
groot korneale defekte met hierdie selle bedek en genesing versnel. Neem asseblief kennis dat 
u versoek sal word om aan te dui of u kornea en stamselle gestoor mag word vir verdere 
navorsing. Dit mag dalk selfs later moontlik wees om volledige korneas buite die liggaam te 
kweek en om hulle oor te plant! 
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Baie dankie vir die voorreg om u wegdoenbare kornea te gebruik vir hierdie navorsingsprojek. 
Neem asseblief kennis dat u kornea of stamselle hoegenaamd nie vir enige finansiële gewin 
gebruik sal word nie. 
Kontak my gerus per spoed-bel 76622 of telefoon 021 404 3525, indien u enige vrae het in 
verband met hierdie navorsingsprojek. 
By voorbaat dank. 
Dr Leonard G. Heydenrych 
Departement Oftalmologie  
UNIVERSITEIT VAN KAAPSTAD  
Fakulteit van Gesondheidswetenskappe 
Navorsings Etiese Komitee 
E52-23 Ou Hoofgebou, Groote Schuur Hospitaal, Observatory, 7925 








Sikhankasa uphando malunga ne glasi yeliso 
February 2010 
Mguli obekekileyo  
Siyabulela kakhulu ngokuthatha le ngxaxheba koluphando lwale Project sithi xa siyibiza 
Cornealstem (Glasi yeliso) 
Ugqirha wakho kuqala uzaku cacisela malunga nale projethi kwakhona aphinde akuxelele 
malunga nokususwa kwale glasi yeliso ngoba yiyo eyonzakalisa amehlo akho ungaboni kakuhle 
ngamehlo akho. 
Phambi kokuba enze yonke into, uzakuxelela ukuba wawukhewafumana ingozi? Ukuba kunjalo 
ugqirha uqala athethe nawe akucacisele umonakalo owenzekayo kuwe. 
Koluphando ugqirha ngemvume yakho mguli uzakususa lento yonzakalisa iliso lakho 
ayisebenzise koluphando. 
Koluphando ugqirha uzakusebenzisa uzenzele (we glasi yeliso) ukwenzela ukuba amajoni la 
afumaneka apha elisweni lakho akwazi ukusebenza ngokwesiqhelo 
Oku kukuzama ukunceda wean mguli, bafake la majoni (cells) akhule abe maninzi apha elisweni. 
Ngoku sebenza kwawo apha ngemva kwi (cornea) I glasi yeliso ibe yimpumelelo enkulu, 




Koluphando mguli unalo ilungelo lokuthi hayi ukubaawuqondi okanye uvume xa uyivile ingxelo 
kagqirha yokutyalwa kwajoni apha elisweni koluphando. 
Ndiqinisekile ngenye imini, sakutyala (cornea) glasi phantsi kwalendlela sityala ngayo. 
Ndiyabulela kakhulu ngokundivumela koluphando nceda uqonde ukuba ngezi glasi cornea 
sizakuzisebenzisa ngendlela ephucukileyo. 
Tsalela umnxeba kule nombolo (speed dial) 76622 okanye nanku omnye umnxeba cofa amanani 
(021)404-3525 ubuze imibuzo wamkelekile. 
Ozithobileyo  
Dr Leonard G. Heydenrych 
UNIVERSITY OF CAPE TOWN  
Faculty of Health Sciences 
Research Ethics Committee 
E52-23 Old Main Building, Groote Schuur Hospital, Observatory, 7925 








Consent taken by medical professional:            
…………………………………………………………………..  (Name)                                                                                          
…………………………………………………………………..   (Signature)  
…………………………………………………………………..  (Date)    
 
Consent taken by medical professional:             
…………………………………………………………………..  (Name)                                                                                          
…………………………………………………………………..   (Signature)  





Consent given by patient and donor: 
Date: …………………………………………………………… 
I, …………………………………………………………………. (Full name) 





…………………………………………………………………..  (Date of birth) 
…………………………………………………………………..  (Hospital Number) 
 
hereby consent for the use of my eviscerated cornea for the sole purpose of stem cell research. 
I also consent that blood will be taken from me for further tests, including the HIV blood test. 
I also agree/disagree that my cornea and stem cells may be stored for an indefinite period of 




Should I so wish, I acknowledge that I have the right to refuse at any time that my donated 
cornea be used for this research project. I have been counseled that this research is voluntary 
and that I can withdraw my consent at any time without prejudice. 
I have also clearly been informed by the researchers that my cornea and stem cells will not be 
used for any financial gain of any source whatsoever. I hereby also consent that research 
obtained through the use of my stem cells and cornea may be published without the use or 
mention of my name.  
Please contact the research leader, Dr Leonard Heydenrych, on Ward D4, telephone 021 404 












Toestemming geneem deur mediese praktisyn: 
…………………………………………………………………..  (Volle naam) 
…………………………………………………………………..  (Handtekening) 
…………………………………………………………………..  (Datum) 
 
Toestemming geneem deur mediese praktisyn: 
 
…………………………………………………………………..  (Volle naam) 
…………………………………………………………………..  (Handtekening) 





Toestemming verleen deur pasiënt en donor:  
Datum: ……………………………………………………. 
Ek, ……………………………………………………………  (Volle naam)                                                                                                                           




…………………………………………………………………..  (Geboortedatum)                                                                                                                      
…………………………………………………………………..  (Hospitaalnommer) 
 
verleen hiermee toestemming vir die gebruik van my ge-evisereerde kornea vir die alleenlike 
doel van stamselnavorsing. Ek verleen hiermee ook toestemming dat bloed van my getrek mag 
word vir verdere toetse, insluitend MIV-toetsing. 
Ek aanvaar/weier dat my kornea en stamselle gestoor mag word vir ‘n onbepaalde tyd vir 
verdere navorsing in hierdie veld (Omkring asseblief die toepaslike opsie). 
Sou dit my wens wees, aanvaar ek dat ek die reg het om enige tyd te weier dat my gedoneerde 
kornea vir hierdie navorsingsprojek gebruik word. Ek is meegedeel dat hierdie navorsing 
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vrywillig is en dat ek my toestemming enige tyd mag onttrek sou dit my wens wees, sonder 
enige vooroordele teenoor my. 
Ek is ook volledig in kennis gestel dat my kornea en stamselle vir geen finansiële doel gebruik 
sal word nie. 
Ek verleen hiermee ook toestemming dat navorsing ingewin deur die gebruik van my kornea en 
stamselle, gepubliseer mag word sonder die gebruik van my naam.  
Indien u enige navrae het in verband met die beoogde navorsing, kan u vir Dr. Leonard 
Heydenrych, die navorsingsleier, kontak by spoed bel 76622, of telefoonnommer 021 404 3525 













Isifungo sithathwe ngu gqirha: 
…………………………………………………………………..  (Igama) 
…………………………………………………………………..  (Tyikitya) 
…………………………………………………………………..  (Umhla) 
 
Isifungo sithathwe ngu gqirha: 
…………………………………………………………………..  (Igama) 
…………………………………………………………………..  (Tyikitya) 





Isifungo sinikwe sisiguli kunye nomnikeli: 
Umhla: ……………………………………………………… 
Mna, ………………………………………………………….  (Igama elipheleleyo) 





…………………………………………………………………..  (Umhla wokuzalwa) 
…………………………………………………………………..  (Inombolo yesibhedlele) 
Oku kukuvuma kokukhutshwa kwe mehlo lam (cornea) ukwenzela uphando lwakwa stem cell 
research. 
Nanini na ndinalo ilungelo lokungavumi okuba imehlo endinikele ngalo lungasetyenziselwa 
oluphando. 
Ndichazelwe ngabo phando ukuba imehlo (cornea and stem cells) aluzusetyenziselwa  ingeniso 
nayaluphina uhlobo. 




Koluphando uyakwazi ukunikezela okanye unganikezeli ngeliso lakho kuxhomekeke kuwe mguli 
ngayo, yonke into ezakwenziwa. 
Okwesibini unalo ilungelo lokuthi hayi xa ungafuni igama likhutshewe kuxelelwe abanye abantu 
okanye koma bona kude.  
Tsalela lo mnxeba umphathi, Dr Leonard Heydenrych kweli candela labaguli ward D4  
( 021 ) 404 - 3225 okanye ( Speed dial ) 76622 
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UNIVERSITY OF CAPE TOWN 
25 February 2011 
HREC REF: 067/2010 
Df L Heydenrych 
Opthalmology 
Drar Dr Heydenrych 
Faculty of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6626 • Facsimile [021] 406 6411 
e-mail: lamees.emjedi@uct.ac.za 
PROJECT TITLE: REVIEWING THE EX VIVO GROWTH PATIERN AND CHARACTERISTICS OF CULTURED CORNEAL 
AND LIMBAL STEM CELLS ON AMNIOTIC MEMBRANE AND APPROPRIATE SUBSTRATES 
Thank you for submitting your progress report to the Faculty of Health Sciences Human Research Ethics 
Committee. 
lt,is a pleasure to inform you that the FHS HREC has granted annual approval for the above-mentioned study. 
Approval is granted for one year until 28 February 2012. 
Please send us an annual progress report (website form FHS 016) if your research continues beyond the approval 
p~riod. Alternatively, please send us a brief summary of your findings so that we can close the research file. 
Please note that the ongoing ethical conduct of the study remains the responsibility ofthe principal investigator. 
· - -·Please quote the REC. REF in all your correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN Pf CHAIRPERSON. HSF HUMAN ETHICS 
lemje<li 
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Current Eye Research Instructions to Authors 
 
Thank you for choosing to submit your paper to us. These instructions will ensure we have 
everything required so your paper can move through peer review, production and publication 
smoothly. Please take the time to read and follow them as closely as possible, as doing so will 
ensure your paper matches the journal’s requirements. For general guidance on the publication 
process at Taylor & Francis please visit our Author Services website.  
2015 Impact Factor: 2.025 
 
 
This journal uses ScholarOne Manuscripts (previously Manuscript Central) to peer review 
manuscript submissions. Please read the guide for ScholarOne authors before making a 
submission. Complete guidelines for preparing and submitting your manuscript to this journal 
are provided below.  
Instructions for Authors 
Submission of Manuscripts 
Manuscripts must be submitted through the journal’s website 
http://mc.manuscriptcentral.com/ncer. Paper manuscript submissions are not accepted. Full-
length papers comprise the major part of each issue. Mini-reviews are accepted for publication 
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only if they have been invited by the Editors. Authors who would like to submit a mini-review 
on a topic in which they have expertise are asked to communicate their interest to the Editors. 
It is the responsibility of the authors to ensure that their papers are in correct English, both 
grammatically and stylistically, before submission. Papers with substantial defects in English will 
be returned without review. One of the Editorial Board members, Dr. Kathryn Pokorny 
(pokornkl@njms.rutgers.edu) can often help authors for a fee.  
 
Current Eye Research strives to publish papers of high quality involving clinical research, 
epidemiology, anatomy, genetics, physiology, biophysics, biochemistry, pharmacology, 
psychophysics, developmental biology, microbiology and immunology, related to the eye and 
vision.  However, there are some restrictions.  Current Eye Research does not publish case 
reports or papers simply describing a new surgical technique, and rarely considers retrospective 
clinical studies.  Papers concerning genetics will generally have to go beyond defining a single 
gene alteration in a small number of individuals.  Papers using any immortalized cell line must 
demonstrate that the cells have the genotype and phenotype of the cells that they are designed 
to represent.  Because of the problems with RCG-5 cells, Current Eye Research will not accept 
papers using this cell line.  Another problematic cell line is ARPE-19, which does not develop 
typical epithelial cell polarization, and may not be entirely representative of the retinal pigment 
epithelium.  If this cell line is used, results should be validated with another cell line or freshly 






The Editors and Taylor & Francis Group are committed to the highest academic, professional, 
legal, and ethical standards in publishing work in this journal. To this end, we have adopted a 
set of guidelines, to which all submitting authors are expected to adhere, to assure integrity 
and ethical publishing for authors, reviewers, and editors.  
Taylor & Francis is a member of the Committee of Publications Ethics (COPE). COPE aims to 
provide a forum for publishers and editors of scientific journals to discuss issues relating to the 
integrity of their work, including conflicts of interest, falsification and fabrication of data, ethical 
misconduct, unethical experimentation, inadequate subject consent, and authorship disputes. 
For more information on COPE please visit http://publicationethics.org.  
 
CrossCheck  
Please note that Current Eye Research uses CrossCheck™ to screen papers for unoriginal 
material. By submitting your paper to the journal you are agreeing to originality checks during 
the peer-review and production processes.  
 
Rapid Publication  
Publication is driven entirely by editorial considerations and independent authoritative peer 
review. As part of the journal’s responsive approach, we would offer a prioritised mode of rapid 





This offers the most highly prioritised service, with a submission to online publication timeline 
of 5–7 weeks (subject to 1–2 week author revision following initial peer-review and prompt 
turnaround of proofs). There is a publication support fee for this, based on a charge of 
$850/€625/£550 per published page. This charge supports the ultra-swift processing of material 
and 20 downloads of the article via e-access tokens. FastTrack papers will be reviewed by the 
Editors for suitability. 
 
StandardTrack 
 This standard service provides submission to online publication in up to 20 weeks; there are no 
publication support fees charged for this mode. 
We welcome contact with the Editorial Offices preceding formal submission and particularly 
encourage prior contact for FastTrack submissions where a particular publication deadline is 
desired. 
 
Length of Manuscripts 
The maximum word count and illustrations including tables is: 
 Full Papers - 5000 words, 8 illustrations / tables 
 Short Communications - 1500 words, 4 illustrations / tables 
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 Mini Reviews - 7000 words, 10 illustrations / tables 
Authors who wish to contribute a mini review should first contact one of the editors-in-chief, 
Gerd Geerling (Geerling@med.uni-duesseldorf.de) for topics concerning the anterior eye, or 
Robert Linsenmeier (r-linsenmeier@northwestern.edu) for topics concerning the posterior eye 
for permission and guidance.  
The journal accepts letters (not to exceed 750 words) only if they are concerning articles 
already published in Current Eye Research.  
Announcements of forthcoming meetings, courses, etc., may be published. The editors will also 
consider special issues containing papers on focused topics or from a conference.  
Each manuscript must be accompanied by a statement that it has not been published 
elsewhere and that it has not been submitted simultaneously for publication elsewhere. 
Current Eye Research follows the guidelines of the International Committee of Medical Journal 
Editors, which generally prohibits duplicate publication 
(http://www.icmje.org/publishing_4overlap.html).  It is also the responsibility of the lead or 
corresponding author to indicate on the manuscript title page whether a commercial 
relationship existed in the form of financial support or personal financial interest. Financial 
support includes support from a for-profit company in the form of research funding. Personal 
financial interest includes company investments (other than mutual or retirement funds) and 
employee or competing company business interests that are the subject matter of the authors’ 
paper, products that the author(s) invented/developed that are the subject matter of the 
article or competition of the subject matter, and gifts in kind, honoraria, or travel 
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reimbursement valued at $1000 in the last 12 months from a company or competing company 
that provides a product or service that is the topic of your article. 
Authors are responsible for obtaining permission to reproduce copyrighted material from other 
sources and are required to sign an agreement for the transfer of copyright to the publisher. As 
an author you are required to secure permission if you want to reproduce any figure, table or 
extract text from any other source. This applies to direct reproduction as well as "derivative 
reproduction" (where you have created a new figure or table which derives substantially from a 
copyrighted source).  
All accepted manuscripts, artwork, and photographs become the property of the publisher. All 
parts of the manuscript should be written in a clear font, such as Times New Roman or Arial, 
double-spaced, with margins of at least one inch on all sides.  The main text and tables should 
be uploaded as Word documents. Do not include line numbers. Manuscript pages should be 
numbered consecutively throughout the paper.  
Authors should provide a cover letter that should include the contact details of the 
corresponding author.  Authors should briefly explain why their work is appropriate for Current 
Eye Research.   
During the submission process, authors are asked to provide the names of at least two 
preferred reviewers.  Information about their affiliations (institution and department) should be 
provided so that the editors can determine whether they are appropriate reviewers.  
Please note - full completion of the "Add a Reviewer" section is required as this may well speed 
up the review process in cases where referees are difficult to locate or unavailable. Please do 
not suggest anyone from the same department as any of the authors.  
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All authors should adhere to the following timeframe when submitting revisions of their 
manuscripts: 
 Minor revisions: 30 days 
 Major revisions: 60 days 
 Reject and resubmit: 180 days 
 
Manuscript Structure  
Title page. This should list the title of the article and the full names (first name, middle initial, 
surname) and institutional addresses for all authors. The e-mail address of the corresponding 
author should also be included. 
Abstract. A structured abstract of no more than 300 words is to be provided, divided into the 
following sections: Purpose/Aim of the study, Materials and Methods, Results, and Conclusions. 
Avoid abbreviations, diagrams, and reference to the text in the abstract. Up to five key words 
should be listed beneath the abstract.  
Main Text. Use the following structure: Introduction, Materials and Methods, Results, and 
Discussion.  
Funding. List all sources of funding for the research.  
Declaration of Interests. Declare any competing interests for each author.  
Acknowledgments. This section is for acknowledging individuals and institutions whose 




References.  References should be identified in the text by Arabic numerals and numbered in 
the order cited. All references should be compiled at the end of the article in the Vancouver 
style.  See below for further details. 
Tables.  
Figure legends. 
Declaration of interest: 
It is the policy of all Taylor and Francis to adhere in principle to the Conflict of Interest policy 
recommended by the International Committee of Medical Journal Editors (ICMJE). 
(http://www.icmje.org/index.html#conflict) 
All authors must disclose any financial and personal relationships with other people or 
organizations that could inappropriately influence (bias) their work. It is the sole responsibility 
of authors to disclose any affiliation with any organization with a financial interest, direct or 
indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, 
employment, paid expert testimony, honoraria, speakers bureaus, retainers, stock options or 
ownership, patents or patent applications or travel grants) that may affect the conduct or 
reporting of the work submitted. All sources of funding for research are to be explicitly stated. 
If uncertain as to what might be considered a potential conflict of interest, authors should err 
on the side of full disclosure. 
All submissions to the journal must include full disclosure of all relationships that could be 
viewed as presenting a potential conflict of interest. If there are no conflicts of interest, authors 
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should state that there are none. This must be stated at the point of submission (within the 
manuscript after the main text under a subheading "Declaration of interest" and where 
available within the appropriate field on the journal’s Manuscript Central site). This may be 
made available to reviewers and will appear in the published article at the discretion of the 
Editors or Publisher. 
If no conflict is declared, the following statement will be attached to all articles: 
Declaration of interest: The authors report no conflicts of interest. The authors alone are 
responsible for the content and writing of the paper. 
The intent of this policy is not to prevent authors with these relationships from publishing work, 
but rather to adopt transparency such that readers can make objective judgments on 
conclusions drawn. 
References 
The journal uses the Vancouver style of referencing.  References are numbered in the text. The 
reference list at the end of the paper should be numbered and arranged in the order in which 
references are cited in the text.   
References should include in the following order: Authors' surnames and initials; title of article; 
title of journal abbreviated according to the style of Index Medicus; year of publication; volume; 
first and last pages of article. 





Journal article (print): Tsubota K, Yamada M. Tear evaporation from the ocular surface. Invest 
Ophthalmol Vis Sci. 1992;33:2942–2950.  
Journal article (print, more than six authors): See JL, Chew PT, Smith SD, Nolan WP, Chan Y-H, 
Huang D et al. Changes in anteri or segment morphology in response to illumination and after 
laser iridotomy in Asian eyes: an anterior segment OCT study. Br J Ophthalmol. 2007;91:1485–
1489.  
Book: Bill A, Maepea O. Mechanisms and Routes of Aqueous Humor Drainage. Philadelphia: WB 
Saunders; 1975. 
Contribution to a Book: Farris RL. Abnormalities of the tears and treatment of dry eyes. In: 
Kaufman HE, Barron BA, McDonald MB, eds. The Cornea. 2nd ed. Boston, MA: Butterworth-
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Tables and Figures 
 Tables and figures should not be embedded in the text, but should be included as separate 
sheets or files. A short descriptive title should appear above each table with a clear legend and 
any footnotes suitably identified below. All units must be included. Figures should be 
completely labeled, taking into account necessary size reduction. 
Captions should be typed, double-spaced, on a separate sheet. All original figures should be 





 Illustrations submitted (line drawings, halftones, photos, photomicrographs, etc.) should be 
clean originals or digital files. Digital files are recommended for highest quality reproduction 
and should follow these guidelines: 
 300 dpi or higher 
 sized to fit on journal page 
 EPS, TIFF, or PSD format only 
 submitted as separate files, not embedded in text files 
 
Color Reproduction 
Color art will be reproduced in color in the online publication at no additional cost to the 
author. Color illustrations will also be considered for print publication; however, the author will 
be required to bear the full cost involved in color art reproduction.  
Please note that color reprints can only be ordered if print reproduction costs are paid. Print 
Rates: $900 for the first page of color; $450 per page for the next three pages of color. A 
custom quote will be provided for articles with more than four pages of color. Art not supplied 







All proofs must be corrected and returned to the publisher within 48 hours of receipt. If the 
manuscript is not returned within the allotted time, the editor will proofread the article and it 
will be printed per the editor’s instruction. Only correction of typographical errors is permitted.  
 
Complimentary Policy and Reprints 
Authors for whom we receive a valid email address will be provided an opportunity to purchase 
reprints of individual articles, or copies of the complete print issue. These authors will also be 
given complimentary access to their final article on Taylor & Francis Online. 
 
Open Access  
Articles are eligible for Open Access. Electing this option allows the article to be made freely 
available online under a Creative Commons License. Authors of accepted papers will have the 
opportunity to purchase open access at proofs stage. Please note: This option is separate from 
Taylor and Francis's NIH fund policy.  
 
NIH Research Policy  
NIH-funded authors must submit to PMC, or have submitted on their behalf, at the point of 
acceptance, their peer-reviewed author manuscripts, to appear on PMC no later than 12 
months after final publication.  
In consideration of the National Institutes of Health (NIH) Public and Open Access Policies, the 
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Taylor and Francis journals group acknowledges that the broad and open dissemination of NIH -
funded research results can benefit future scientific and medical research.  
As part of our author services program, Taylor and Francis will assist authors in depositing to 
PubMed Central (PMC) author manuscripts reporting NIH funded research, on specific request 
by the author. Upon this request, Taylor and Francis will deliver to PMC the final peer-reviewed 
manuscript, which was accepted for publication and that reflects any author-agreed changes 
made in response to the peer review. We will also authorize the manuscript’s public access 
posting 12 months (NIH) after initial publication in print or electronic form (whichever is 
sooner). Following the deposit, authors will receive further communications from the NIH 
Manuscript Submission System with respect to the submission.  
Authors wishing to submit their funded work to PMC themselves are welcome to do so 
providing they follow the terms stated – submitting only the final peer-reviewed manuscript 
which was accepted for publication (this manuscript must not be altered by Publisher’s 
copyediting and typesetting services) and stating the 12 month (NIH) embargo period after final 
publication.  
Please note that authors should not deposit post-print manuscripts directly to PMC or other 
third party sites for any systematic external distribution by a third party (e.g., to a listserv or 
database connected to a public access server). 
All authors must comply with our editorial polices. 
